Breathomix

Breathomix is a Netherlands-based company that has developed an electronic nose (eNose) technology called SpiroNose for analyzing exhaled breath to diagnose respiratory diseases and conditions like asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and other illnesses. The SpiroNose device contains sensors that measure the complete mixture of volatile organic compounds (VOCs) present in exhaled breath, creating an individual breathing profile for each patient.

This breathing profile is then analyzed and compared to a reference database containing breathing profiles and clinical data of thousands of patients with known diagnoses. By employing artificial intelligence (AI) techniques, the SpiroNose can accurately determine the most likely diagnosis for a new patient based on their breathing profile. The device measures both exhaled air and ambient air, sending the data to the BreathBase platform for analysis, correction, and comparison with reference values.

Breathomix's eNose technology has shown promising results in various studies. In June 2021, researchers touted the eNose's potential to predict immunotherapy response in mesothelioma patients, helping identify those unlikely to benefit and avoid unnecessary side effects. Another study in September 2023 demonstrated the eNose's ability to detect lung cancer development in COPD patients two years before clinical diagnosis, with an accuracy of 90%.

Additionally, in September 2019, a study involving 143 lung cancer patients reported that Breathomix's eNose could predict non-responders to cancer immunotherapies like Opdivo and Keytruda with an accuracy of 85%, significantly higher than current diagnostic methods. The eNose technology has also shown potential in lung transplantation, as illustrated by a case study published in July 2022, where it could discriminate between a stable condition and complications like acute cellular rejection and bacterial pneumonia after lung transplantation.